Articles

A recently developed urine test can assist in the early detection of and treatment decisions regarding prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.

Designed to supplement an elevated prostate-specific antigen (PSA) screening result, this test also defines men at highest risk for clinically significant prostate cancer and could delay or negate the need for a needle biopsy in some patients.

BOSTON—The national discourse on cancer screening has come a long way since 1988, when Ronald Reagan became the first president to say “breast cancer” in public, noted Alec Stone, MA, MPA, Health Policy Director, Oncology Nursing Society (ONS). After the US Preventive Services Task Force (USPSTF) recommended mammography screening every 2 years instead of annually, beginning at 50 years of age instead of 40, the public outcry was widespread and loud. Controversy has also been swirling about prostate cancer screening recommendations.

Maintaining a healthy body weight is important for all patients. But this is especially true for women with a breast cancer diagnosis, as an analysis of the California Teachers Study has shown a correlation between breast cancer deaths and body mass index (BMI).

Obesity (defined as BMI ≥30 kg/m²) increased a woman’s risk of dying of her breast cancer by 69%, compared with a woman with a BMI <25. For patients who were overweight at 18 years of age (defined as BMI 25-29), a similar increased risk in breast cancer mortality was detected.

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy.

Increased awareness, earlier detection through screening, and advances in treatment have led to a decline in breast cancer death rates in the United States since 1990. Sadly, breast cancer continues to claim more women’s lives than any other cancer, besides lung cancer. For more statistical data on this prevalent disease, let’s take a look at breast cancer by the numbers.

About 1 in 8 (12%) women in the United States will develop invasive breast cancer over the course of her lifetime.

BOSTON—Treating patients with cancer who are morbidly obese presents unexpected challenges according to Vita Norton, RN, BSN, OCN, and Michelle Howard, RN, BSN, of Mass - achusetts General Hospital in Boston. Data indicate that obesity significantly increases the risk of endometrial and ovarian cancers and is associated with worse outcomes.

Case Presentation

Chief complaint: Generalized arthralgia for 5 months.

BOSTON—Recognizing steroid-induced hyperglycemia early and addressing it promptly can prevent significant ad - verse effects associated with this complication. Educating patients on the importance of and methods for maintaining good blood glucose control helps mitigate damage to the vascular system and kidneys from hyperglycemia. It also lessens susceptibility to infection, a complication of hyperglycemia that is of serious concern in immunocompromised patients. Read More ›

Trastuzumab is a monoclonal antibody that affects the human epidermal growth factor receptor-2 (HER2).  Trastuzumab is frequently used in young women diagnosed with HER2 breast cancer. A new study by Dr César Serrano et al published in Annals of Oncology found that trastuzumab increases the risk of heart problems, particularly in elderly women with a history of heart disease, diabetes, or both.